March 25, 2026 – Merck (MSD outside the U.S. and Canada) has entered into a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, valuing the company at $6.7 billion. The deal brings Merck access to TERN-701, a novel oral therapy for chronic myeloid leukemia (CML) that targets the ABL myristoyl pocket, offering a differentiated mechanism compared to existing ATP-site tyrosine kinase inhibitors.
Key Highlights:
- Clinical Asset: TERN-701, currently in Phase I/II trials, shows promising efficacy and safety in patients with resistant CML mutations, including T315I.
- Strategic Fit: Expands Merck’s oncology portfolio and reinforces its commitment to next-generation hematology therapies.
- Regulatory Milestone: TERN-701 received FDA Orphan Drug Designation in March 2024.
- Financial Impact: Merck expects a ~$5.8B charge in Q2 and FY 2026 results.
Merck CEO Robert M. Davis commented:
The acquisition of Terns builds on our growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia.
Anveta’s Perspective
At Anveta Therapeutics, we see this acquisition as a powerful validation of the co-development model we champion. Merck’s willingness to commit billions based on Phase I/II data underscores how early translational innovation—when nurtured and advanced with rigor—can create extraordinary value for patients and investors alike.
This deal highlights three themes central to Anveta’s mission:
- Academic Innovation Meets Industry Execution: Terns’ scientific insight translated into a clinical-stage asset compelling enough to attract global pharma.
- Partnership as a Growth Engine: Strategic collaborations and acquisitions are increasingly the path by which breakthrough science reaches patients faster.
- Translational Impact: Even early clinical signals, when well-designed and well-executed, can shift the trajectory of treatment landscapes.
For Anveta, this reinforces our belief that keeping originating researchers engaged through early clinical development is not just good science it’s good business.